Naslov
Neoadjuvant oncolytic virotherapy of a localized breast cancer recurrence – a case study

Autori
Dubravko Forčić, Karmen Mršić, Melita Perić-Balja, Tihana Kurtović, Snježana Ramić, Tajana Silovski, Ivo Pedišić, Ivan Milas, Beata Halassy

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
“HDIR-6: Targeting Cancer” The 6th Meeting of the Croatian Association for Cancer Research with International Participation / - , 2022, 30-30

Skup
6th Meeting of the Croatian Association for Cancer Research with International Participation: Targeting Cancer (HDIR-6)

Mjesto i datum
Zagreb, Hrvatska, 10.11.2022. - 12.11.2022

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Intratumoral oncolytic virotherapy ; breast cancer ; MeV ; VSV

Sažetak
Intratumoral oncolytic virotherapy may have promise as a means to debulk and downstage inoperable tumours in preparation for successful surgery. Here we describe the pioneering case of a 50-year-old virologist with locally recurrent muscle-invasive breast cancer who was able to proceed to tumour resection after receiving multiple intratumoral injections of viruses, first an Edmonston Zagreb measles vaccine strainMeV) then vesicular stomatitis virus Indiana strain (VSV). The intratumoral virus therapy was well tolerated and led to transient pseudoprogression followed by partial tumour remission. Frequent imaging studies and regular clinical observations documenting size, consistency and mobility of the injected tumour demonstrate that both MeV and VSV contributed to the overall favourable response. Two months after the start of virus injections, the shrunken tumour was no longer invading the skin or underlying muscle and was surgically excised. The excised tumour showed strong lymphocytic infiltration, with increase in both CD20-positive B cells and CD8-positive T cells, as well as macrophages. PD-L1 expression was detected in contrast to the PD-L1 negative phenotype before the treatment. The patient completed one-year trastuzumab adjuvant therapy, remains well and recurrence free 22 months post-surgery. Although an isolated case, the study provides a strong rationale for the formal testing of oncolytic virotherapy also in patients with early stage cancer.

Izvorni jezik
Engleski

POVEZANOST RADA